3,5-二氟-2-羟基苯硼酸 | 1150114-51-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3,5-二氟-2-羟基苯硼酸
• 中文别名: 3,5-二氟-2-羟基苯基硼酸
• 英文名称: (3,5-difluoro-2-hydroxyphenyl)boronic acid
• 英文别名: 3,5-Difluoro-2-hydroxyphenylboronic acid
• CAS: 1150114-51-4
• 化学式: C₆H₅BF₂O₃
• mdl: MFCD03095356
• 分子量: 173.912
• InChiKey: DMZXNOGEVAESIC-UHFFFAOYSA-N

物化性质

• 沸点：
  318.4±52.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.63
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,5-Difluoro-2-hydroxyphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,5-Difluoro-2-hydroxyphenylboronic acid
CAS number: 1150114-51-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5BF2O3
Molecular weight: 173.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二氟-2-羟基苯硼酸 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 水 、 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 28.0h， 生成 2,4-difluoro-6-(5-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenol
  参考文献：
  名称：

  [EN] SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS
  [FR] DÉRIVÉS SUBSTITUÉS DE 1H-PYRROLO[2,3-B]PYRIDINE ET 1H-PYRAZOLO[3,4-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASES 2 INDUCTIBLES PAR UN SEL (SIK2)

  摘要：

  本发明涉及符合以下公式I、IA或IB的化合物：药学上可接受的组合物、其盐、它们的合成以及它们作为SIK2抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或紊乱的方法，如癌症、中风、心血管疾病、肥胖和2型糖尿病。

  公开号：

  WO2014093383A1
• 作为产物：
  描述：

  3,5-二氟-2-甲氧基苯硼酸 在 三溴化硼 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以72%的产率得到3,5-二氟-2-羟基苯硼酸
  参考文献：
  名称：

  [EN] THIAZOLE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF (INTER ALIA) CARDIOVASCULAR DISEASES
  [FR] COMPOSÉS THIAZOLE UTILISÉS COMME ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE

  摘要：

  公开号：

  WO2010015652A3

文献信息

• [EN] PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] MACROCYCLES DE PYRAZOLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015126376A1

  公开（公告）日：2015-08-27

  The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及到I式化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• [EN] BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS BIFONCTIONNELS POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021083949A1

  公开（公告）日：2021-05-06

  The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).

  该发明提供了式（I）的双功能化合物或其药用可接受的盐。式（I）。这些化合物通过靶向泛素化SMARCA2蛋白并随后的蛋白酶体降解来导致SMARCA2的降解，因此对于癌症的治疗是有用的。靶向配体的化学式为（TL）。
• Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer
  作者：Wei Zhu、Hui Chen、Yulan Wang、Jiang Wang、Xia Peng、Xianjie Chen、Yinglei Gao、Chunpu Li、Yulong He、Jing Ai、Meiyu Geng、Mingyue Zheng、Hong Liu

  DOI：10.1021/acs.jmedchem.7b00076

  日期：2017.7.27

  derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast growth factor receptors (FGFR), which was subsequently validated by in vitro experiments. The structure–activity relationship (SAR) of its analogues was then explored to afford novel FGFR

  设计，合成和评估了一系列新颖的吡啶-3-胺衍生物，作为多靶点蛋白激酶抑制剂用于非小细胞肺癌（NSCLC）的治疗。首先通过计算机筛选针对成纤维细胞生长因子受体（FGFR）的命中1，随后通过体外实验对其进行了验证。然后研究其类似物的结构-活性关系（SAR），以提供新型FGFR抑制剂2a - 2p和3a - 3q。其中3m对FGFR1、2和3表现出有效的抑制作用。有趣的是，化合物3m不仅抑制FGFR过度激活的癌细胞中不同致癌形​​式的各种磷酸化和下游信号传导，而且还显示出对数种其他NSCLC相关癌基因激酶（包括RET，EGFR，EGFR / T790M / L858R，DDR2和ALK）的纳摩尔水平抑制作用。最后，3m的体内药理学评估显示具有良好药代动力学特征的NCI-H1581 NSCLC异种移植物具有显着的抗肿瘤活性（TGI = 66.1％）。
• [EN] MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES SUBSTITUÉS PAR UN BENZYLE MOYEN CYCLE OU MACROCYCLIQUE ET LEURS UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR DE L'OREXINE 2
  申请人：OREXIA THERAPEUTICS LTD

  公开号：WO2022051583A1

  公开（公告）日：2022-03-10

  The present disclosure relates to compounds of Formula (I') and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used m the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

  本公开涉及式(I')的化合物及其前药、药用盐、药物组合物、使用方法和制备方法。本文所披露的化合物可用于调节促脑二受体活性，并可用于治疗促脑二受体活性参与的疾病，如嗜睡症、一种嗜睡症障碍、神经退行性疾病、罕见遗传疾病的症状、心理健康障碍、代谢综合征、骨质疏松症、心力衰竭、昏迷或促进麻醉苏醒。
• Efficient synthesis of diversely substituted pyrimidines by palladium catalyzed Suzuki–Miyaura coupling
  作者：Viral J. Faldu、Pratik K. Talpara、Viresh H. Shah

  DOI：10.1016/j.tetlet.2014.01.042

  日期：2014.2

  An efficient synthesis of 2-aryl/heteroaryl substituted pyrimidinyl ethanones 4(a-t) was developed using a palladium-catalyzed Suzuki-Miyaura coupling reaction strategy. Use of Pd(OAc)(2) in the presence of PPh3 and Na2CO3 in 1,4-dioxane solvent was found to be the most effective reaction condition. (C) 2014 Elsevier Ltd. All rights reserved.